US FDA takes step to change peptide compounding policy

The US FDA has submitted a policy change to the White House that could ease regulations on compounding certain peptides in pharmacies, potentially enabling wider access to these products despite them not being FDA-approved for safety or efficacy.

This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 15 Oct 2026 and 16 Oct 2026.